These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Wan T; Rodger M; Zeng W; Robin P; Righini M; Kovacs MJ; Tan M; Carrier M; Kahn SR; Wells PS; Anderson DR; Chagnon I; Solymoss S; Crowther M; White RH; Vickars L; Bazarjani S; Le Gal G Thromb Res; 2018 Feb; 162():104-109. PubMed ID: 29224973 [TBL] [Abstract][Full Text] [Related]
7. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090 [TBL] [Abstract][Full Text] [Related]
8. Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy. Zabczyk M; Plens K; Wojtowicz W; Undas A Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):365-373. PubMed ID: 28062504 [TBL] [Abstract][Full Text] [Related]
9. Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis. Becattini C; Giustozzi M; Cerdà P; Cimini LA; Riera-Mestre A; Agnelli G J Thromb Haemost; 2019 Aug; 17(8):1217-1228. PubMed ID: 31063646 [TBL] [Abstract][Full Text] [Related]
10. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709 [TBL] [Abstract][Full Text] [Related]
11. [Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial]. Couturaud F; Pernod G; Pison C; Mismetti P; Sanchez O; Meyer G; Parent F; Girard P; Simonneau G; Drouet L; Gueret P; Jego P; Delaval P; Duhamel E; Gruel Y; Delahousse B; Regina S; Pottier P; Connaud J; Lecomte F; Provost K; Vilmans N; Gosset X; Bura-Rivière A; Meach G; Lacut K; Bosson JL; Guillot K; Mottier D; Leroyer C Rev Mal Respir; 2008 Sep; 25(7):885-93. PubMed ID: 18946418 [TBL] [Abstract][Full Text] [Related]
12. "HERDOO2" clinical decision rule to guide duration of anticoagulation in women with unprovoked venous thromboembolism. Can I use any d-Dimer? Rodger MA; Le Gal G; Langlois NJ; Gin B; Mallick R; Giulivi A; Freedman M; Kovacs MJ; Thromb Res; 2018 Sep; 169():82-86. PubMed ID: 30031290 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Coleman CI; Bunz TJ; Turpie AGG Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322 [TBL] [Abstract][Full Text] [Related]
14. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221 [TBL] [Abstract][Full Text] [Related]
15. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA; Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712 [TBL] [Abstract][Full Text] [Related]
16. [The optimal duration of anticoagulant treatment following pulmonary embolism]. Couturaud F Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935 [TBL] [Abstract][Full Text] [Related]
17. Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants. Prandoni P; Milan M; Sarolo L; Zanon E; Bilora F Int Angiol; 2017 Oct; 36(5):395-401. PubMed ID: 27982558 [TBL] [Abstract][Full Text] [Related]
18. Unprovoked Venous Thromboembolism: The Search for the Cause. Mwansa H; Zghouzi M; Barnes GD Med Clin North Am; 2023 Sep; 107(5):861-882. PubMed ID: 37541713 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary embolism: update on management and controversies. Duffett L; Castellucci LA; Forgie MA BMJ; 2020 Aug; 370():m2177. PubMed ID: 32759284 [TBL] [Abstract][Full Text] [Related]
20. Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. Robin P; Eddy M; Sikora L; Le Roux PY; Carrier M; Couturaud F; Planquette B; Pesavento R; Rodger M; Salaun PY; Le Gal G BMJ Open; 2018 Nov; 8(11):e023939. PubMed ID: 30498046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]